NCT06433531View on ClinicalTrials.gov

A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

July 8, 2025

Study Completion Date

December 31, 2025

Conditions
Generalized Pustular Psoriasis
Interventions
DRUG

TQH2929 Injection

TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Trial Locations (7)

100871

Peking University First Hospital, Beijing

110000

The First Hospital of China Medical University, Shenyang

310000

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

510091

Dermatology Hospital of Southern Medical Universitye, Guangzhou

610052

Second People's Hospital of Chengdu, Chengdu

050000

The First Hospital of Hebei Medical University, Shijiazhuang

The Second Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY